Poolbeg Pharma plc (AIM: POLB) has appointed Shore Capital as Joint Broker as we continue to develop our healthcare client base.

Poolbeg has a market cap of c.£60m and is dedicated to the development and commercialisation of medicines with a high unmet medical need with an exciting pipeline of drugs covering oncology, infection disease and obesity. The company also leverages AI to accelerate drug discovery, making the development of new drugs more efficient and increasing the chances of success.

We look forward to working with the Poolbeg team.

For further information please contact:  

Shore Capital +44 (0) 20 7408 4090

Corporate Advisory: David Coaten, Harry Davies-Ball

Corporate Broking: Malachy McEntyre, Isobel Jones

For Shore Capital media enquiries, please contact:  

[email protected]